LLY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Eli Lilly (LLY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and dominance in the obesity market make it a compelling investment opportunity despite minor technical weaknesses and insider selling.
The MACD is negative and expanding, RSI is neutral at 44.04, and moving averages are converging, indicating no strong trend. The stock is trading near support levels (S1: 1009.138), which could provide a potential entry point.
Strong Q4 2025 financial performance with 42.56% YoY revenue growth and 50.52% YoY net income growth.
Positive clinical results for orforglipron, outperforming Novo Nordisk's semaglutide.
Analysts maintain high price targets, with RBC Capital, Barclays, and others projecting values between $1,250 and $1,
Congress trading data indicates balanced interest, with significant purchase transactions.
FDA's bonus scheme to improve drug review efficiency could benefit Eli Lilly's pipeline.
Insiders are selling, with a 4519.16% increase in selling activity over the last month.
Technical indicators show no clear upward momentum, and the stock has a 50% chance of declining in the short term.
Hedge funds are neutral, showing no strong institutional support.
Eli Lilly reported exceptional Q4 2025 results, with revenue up 42.56% YoY to $19.29 billion, net income up 50.52% YoY to $6.64 billion, and EPS up 51.43% YoY to $7.39. Gross margin improved slightly to 82.52%.
Analysts are overwhelmingly positive on Eli Lilly, with multiple firms initiating or maintaining Buy/Outperform ratings and raising price targets. RBC Capital and Barclays highlight the company's dominance in the obesity market and undervalued transformative catalysts. Price targets range from $1,200 to $1,350, reflecting confidence in long-term growth.
